Key Insights

Highlights

Success Rate

78% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 49/100

Termination Rate

6.8%

4 terminated out of 59 trials

Success Rate

77.8%

-8.7% vs benchmark

Late-Stage Pipeline

5%

3 trials in Phase 3/4

Results Transparency

50%

7 of 14 completed with results

Key Signals

7 with results78% success

Data Visualizations

Phase Distribution

43Total
Not Applicable (16)
Early P 1 (5)
P 1 (10)
P 2 (9)
P 3 (3)

Trial Status

Recruiting18
Completed14
Not Yet Recruiting8
Enrolling By Invitation6
Active Not Recruiting5
Terminated4

Trial Success Rate

77.8%

Benchmark: 86.5%

Based on 14 completed trials

Clinical Trials (59)

Showing 20 of 20 trials
NCT07642635Phase 1Not Yet RecruitingPrimary

Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy

NCT07423026RecruitingPrimary

A Remote Study Using Technology to Assess Outcomes in DMD

NCT07608432Phase 3RecruitingPrimary

Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)

NCT07609394RecruitingPrimary

Duchenne Electronic Health Record Study

NCT07039799Not ApplicableRecruitingPrimary

The Effect of Virtual Reality Applications on Upper Extremity Functions in Patients With Duchenne Muscular Dystrophy

NCT07038824Phase 1RecruitingPrimary

A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping to Evaluate the Safety and Efficacy of ENTR-601-45

NCT07573631Phase 2Enrolling By InvitationPrimary

An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of BMN 351 in Participants With Duchenne Muscular Dystrophy

NCT07188012Early Phase 1RecruitingPrimary

Safety and Dystrophin Expression of SPOT-03 in Duchenne Muscular Dystrophy (DMD) Patients

NCT07092540RecruitingPrimary

The Baby Duchenne Study: Characterizing Developmental and Clinical Outcomes in the First Three Years in Children With Duchenne Muscular Dystrophy

NCT07565272Enrolling By InvitationPrimary

Usability and User Experience of a Virtual Reality Rehabilitation Game Platform in Individuals With Duchenne Muscular Dystrophy

NCT07543302Not ApplicableEnrolling By InvitationPrimary

Can External Vagus Nerve Stimulation Reduce Systemic Levels of Inflammatory Mediators in Duchenne Muscular Dystrophy Patients?

NCT06867107Phase 2Enrolling By InvitationPrimary

An Open-label Long-term Follow-up Study of SAT-3247 for Participants With Duchenne Muscular Dystrophy Including Those Who Participated in SAT-3247-CL-101

NCT07467187Recruiting

Invasive Home Ventilation in Denmark

NCT07254988Not ApplicableTerminated

Gut Peptides and Bone Remodeling in Children With Neuromuscular Disorders

NCT06839469Recruiting

Establishing Walking-related Digital Biomarkers in Rare Childhood Onset Progressive Neuromuscular Disorders

NCT07347548Phase 1Active Not RecruitingPrimary

A Trial to Investigate the Safety and Pharmacokinetics of GRT6019 in Healthy Male Participants

NCT07332013Not ApplicableRecruitingPrimary

Urinary Titin Biomarker in DMD

NCT07475754Not ApplicableNot Yet RecruitingPrimary

A Study to Evaluate the Safety and Tolerability of Rituxan in Duchenne Muscular Dystrophy

NCT04322357Phase 2CompletedPrimary

Twice Weekly Steroids and Exercise as Therapy for DMD

NCT07037862Phase 1RecruitingPrimary

A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44

Scroll to load more

Research Network

Activity Timeline